Personalis (NASDAQ:PSNL) Releases Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Personalis (NASDAQ:PSNL) released its quarterly earnings data on Thursday. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.32) by $0.09, Zacks reports. Personalis had a negative return on equity of 66.07% and a negative net margin of 104.52%. Personalis updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Personalis Price Performance

Shares of NASDAQ:PSNL opened at $4.24 on Friday. The company has a market capitalization of $299.55 million, a PE ratio of -2.52 and a beta of 1.73. The business has a fifty day moving average price of $5.43 and a two-hundred day moving average price of $5.04. Personalis has a 1 year low of $1.13 and a 1 year high of $7.20.

Wall Street Analysts Forecast Growth

PSNL has been the subject of several recent research reports. Needham & Company LLC decreased their price target on Personalis from $7.25 to $7.00 and set a “buy” rating for the company in a report on Friday. Lake Street Capital upped their price target on Personalis from $7.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of Personalis in a report on Friday.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.